ASCO 2022 | postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapy

Kevin Kalinsky, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, provides an overview of the rationale and design of the postMONARCHE study (NCT05169567), a Phase III study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.